Lars Magne Eri

  • Consultant urologist; MD, PhD
  • +47 23 03 41 11, 909 40 376
 

Publications 2024

Qvigstad LF, Eri LM, Lien MD, Fosså SD, Aas K, Berge V (2024)
Reduction of lower urinary tract symptoms in prostate cancer patients treated with robot assisted laparoscopic prostatectomy
Scand J Urol, 59, 121-125
DOI 10.2340/sju.v59.40070, PubMed 38888041

Publications 2022

Guldvik IJ, Braadland PR, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, Røder A, Schlomm T, Berge V, Eri LM, Lilleby W, Mills IG, Taskén KA (2022)
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
Eur Urol Open Sci, 45, 68-75
DOI 10.1016/j.euros.2022.09.002, PubMed 36353660

Publications 2021

Hopland OA, Fosså SD, Ottosson F, Brennhovd B, Svindland A, Hole KH, Hernes E, Eri LM, Diep LM, Berge V (2021)
Robotic salvage pelvic lymph node dissection for locoregional recurrence after radical prostatectomy: a single institution experience
Scand J Urol, 55 (4), 287-292
DOI 10.1080/21681805.2021.1946135, PubMed 34196594

Publications 2019

Fosså SD, Beyer B, Dahl AA, Aas K, Eri LM, Kvan E, Falk RS, Graefen M, Huland H, Berge V (2019)
Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE technique
Scand J Urol, 53 (6), 385-391
DOI 10.1080/21681805.2019.1693625, PubMed 31797716

Publications 2018

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2018)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 118 (6), e11
DOI 10.1038/bjc.2017.470, PubMed 29462127

Johnson I, Ottosson F, Diep LM, Berg RE, Hoff JR, Wessel N, Eri LM, Berge V (2018)
Switching from laparoscopic radical prostatectomy to robot assisted laparoscopic prostatectomy: comparing oncological outcomes and complications
Scand J Urol, 52 (2), 116-121
DOI 10.1080/21681805.2017.1420099, PubMed 29334304

Prencipe M, Fabre A, Murphy TB, Vargyas E, O'Neill A, Bjartell A, Tasken KA, Grytli HH, Svindland A, Berge V, Eri LM, Gallagher W, Watson RW (2018)
Role of serum response factor expression in prostate cancer biochemical recurrence
Prostate, 78 (10), 724-730
DOI 10.1002/pros.23516, PubMed 29608018

Publications 2017

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2017)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 117 (11), 1656-1664
DOI 10.1038/bjc.2017.346, PubMed 28972967

Eri LM (2017)
[Not Available]
Tidsskr Nor Laegeforen, 137 (22)
DOI 10.4045/tidsskr.17.0710, PubMed 29181947

Idland AV, Wyller TB, Støen R, Eri LM, Frihagen F, Ræder J, Chaudhry FA, Hansson O, Zetterberg H, Blennow K, Bogdanovic N, Brækhus A, Watne LO (2017)
Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium
J Alzheimers Dis, 55 (1), 371-379
DOI 10.3233/JAD-160461, PubMed 27662296

Publications 2016

Fosså SD, Storås AH, Steinsvik EA, Myklebust TA, Eri LM, Loge JH, Dahl AA (2016)
Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26)
Scand J Urol, 50 (4), 280-5
DOI 10.3109/21681805.2016.1163617, PubMed 27049891

Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R (2016)
Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA
Clin Nutr, 36 (3), 672-679
DOI 10.1016/j.clnu.2016.06.014, PubMed 27406859

Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA (2016)
PBX3 is a putative biomarker of aggressive prostate cancer
Int J Cancer, 139 (8), 1810-20
DOI 10.1002/ijc.30220, PubMed 27273830

Publications 2015

Baco E, Rud E, Eri L, Oen G, Latkovic L, Svindland A, Eggesbø H, Ukimura O (2015)
[Not Available]
Prog Urol, 25 (13), 832-3
DOI 10.1016/j.purol.2015.08.231, PubMed 26544425

Baco E, Rud E, Eri LM, Moen G, Vlatkovic L, Svindland A, Eggesbø HB, Ukimura O (2015)
A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy
Eur Urol, 69 (1), 149-56
DOI 10.1016/j.eururo.2015.03.041, PubMed 25862143

Eri LM (2015)
[Re: Implementation of guidelines for PSA testing in general practice]
Tidsskr Nor Laegeforen, 135 (1), 15
DOI 10.4045/tidsskr.14.1494, PubMed 25589118

Rud E, Baco E, Klotz D, Rennesund K, Svindland A, Berge V, Lundeby E, Wessel N, Hoff JR, Berg RE, Diep L, Eggesbø HB, Eri LM (2015)
Does preoperative magnetic resonance imaging reduce the rate of positive surgical margins at radical prostatectomy in a randomised clinical trial?
Eur Urol, 68 (3), 487-96
DOI 10.1016/j.eururo.2015.02.039, PubMed 25813692

Publications 2014

Rud E, Klotz D, Rennesund K, Baco E, Berge V, Lien D, Svindland A, Lundeby E, Berg RE, Eri LM, Eggesbø HB (2014)
Detection of the index tumour and tumour volume in prostate cancer using T2-weighted and diffusion-weighted magnetic resonance imaging (MRI) alone
BJU Int, 114 (6b), E32-E42
DOI 10.1111/bju.12637, PubMed 24447606

Rud E, Klotz D, Rennesund K, Baco E, Johansen TE, Diep LM, Svindland A, Eri LM, Eggesbø HB (2014)
Preoperative magnetic resonance imaging for detecting uni- and bilateral extraprostatic disease in patients with prostate cancer
World J Urol, 33 (7), 1015-21
DOI 10.1007/s00345-014-1362-x, PubMed 25059766

Siddiqui H, Lagesen K, Nederbragt AJ, Eri LM, Jeansson SL, Jakobsen KS (2014)
Pathogens in Urine from a Female Patient with Overactive Bladder Syndrome Detected by Culture-independent High Throughput Sequencing: A Case Report
Open Microbiol J, 8, 148-53
DOI 10.2174/1874285801408010148, PubMed 25685246

Publications 2013

Berge V, Berg RE, Hoff JR, Wessel N, Diep LM, Karlsen SJ, Eri LM (2013)
A prospective study of transition from laparoscopic to robot-assisted radical prostatectomy: quality of life outcomes after 36-month follow-up
Urology, 81 (4), 781-6
DOI 10.1016/j.urology.2013.01.017, PubMed 23465150

Publications 2012

Steinsvik EA, Axcrona K, Angelsen A, Beisland C, Dahl A, Eri LM, Haug ES, Svindland A, Fosså S (2012)
Does a surgeon's annual radical prostatectomy volume predict the risk of positive surgical margins and urinary incontinence at one-year follow-up? Findings from a prospective national study
Scand J Urol, 47 (2), 92-100
DOI 10.3109/00365599.2012.707684, PubMed 22860630

Publications 2011

Berge V, Berg RE, Hoff JR, Wessel N, Svindland A, Karlsen SJ, Eri LM (2011)
Five-year progression-free survival in 577 patients operated on with laparoscopic radical prostatectomy for localized prostate cancer
Scand J Urol Nephrol, 46 (1), 8-13
DOI 10.3109/00365599.2011.604790, PubMed 21843041

Steinsvik EA, Axcrona K, Dahl AA, Eri LM, Stensvold A, Fosså SD (2011)
Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother
BJU Int, 109 (9), 1366-74
DOI 10.1111/j.1464-410X.2011.10598.x, PubMed 21999333

Publications 2003

Karlsen SJ, Wahlqvist R, Eri LM, Angelsen A (2003)
Prostatakreft: feilinformasjon og begrepsforvirring
In Dagens medisin, Dagens medisin, Oslo, (2003)7, s.Kronikk og debatt
BIBSYS 041704622

Publications 2002

Eri LM, Thomassen H, Brennhovd B, Håheim LL (2002)
Accuracy and repeatability of prostate volume measurements by transrectal ultrasound
Prostate Cancer Prostatic Dis, 5 (4), 273-8
DOI 10.1038/sj.pcan.4500568, PubMed 12627211

Eri LM, Wessel N, Tysland O, Berge V (2002)
Comparative study of pressure-flow parameters
Neurourol Urodyn, 21 (3), 186-93
DOI 10.1002/nau.10018, PubMed 11948710

Publications 2001

Eri LM, Sivertsen S, Nagelhus J (2001)
The impact of participation in a study of medical treatment of lower urinary tract symptoms on the incidence of prostate surgery
World J Urol, 19 (4), 256-8
DOI 10.1007/s003450000180, PubMed 11550784

Eri LM, Svindland A, Tveter KJ (2001)
The effect of bicalutamide on prostate histology
Prostate, 46 (4), 275-80
DOI 10.1002/1097-0045(20010301)46:4<275::aid-pros1033>3.0.co;2-2, PubMed 11241549

Eri LM, Tveter KJ (2001)
Effects of bicalutamide and leuprolide on prostate-specific antigen (PSA), acid phosphatase (ACP) and prostatic acid phosphatase (PAP) in men with benign prostatic hyperplasia (BPH)
Prostate Cancer Prostatic Dis, 4 (3), 173-177
DOI 10.1038/sj.pcan.4500504, PubMed 12497037

Eri LM, Wessel N, Berge V (2001)
Test-retest variation of pressure flow parameters in men with bladder outlet obstruction
J Urol, 165 (4), 1188-92
DOI 10.1016/S0022-5347(05)66466-X, PubMed 11257668

Fosså SD, Eri LM, Skovlund E, Tveter K, Vatten L, Norwegian Urological Cancer Group (2001)
No randomised trial of prostate-cancer screening in Norway
Lancet Oncol, 2 (12), 741-5; discussion 746-9
DOI 10.1016/S1470-2045(01)00588-5, PubMed 11902516

Publications 2000

Eri LM, Svindland A (2000)
Can prostate epithelial content predict response to hormonal treatment of patients with benign prostatic hyperplasia?
Urology, 56 (2), 261-5
DOI 10.1016/s0090-4295(00)00629-4, PubMed 10925090

Nesbakken A, Nygaard K, Bull-Njaa T, Carlsen E, Eri LM (2000)
Bladder and sexual dysfunction after mesorectal excision for rectal cancer
Br J Surg, 87 (2), 206-10
DOI 10.1046/j.1365-2168.2000.01357.x, PubMed 10671929

Publications 1999

Fosså SD, Eri LM (1999)
[Timely screening routines for prostatic cancer by Norwegian physicians]
Tidsskr Nor Laegeforen, 119 (24), 3572-6
PubMed 10563174

Publications 1997

Eri LM, Tveter KJ (1997)
Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective
Drugs Aging, 10 (2), 107-18
DOI 10.2165/00002512-199710020-00004, PubMed 9061268

Publications 1996

Eri LM, Haug E, Tveter KJ (1996)
Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia
Scand J Clin Lab Invest, 56 (4), 319-25
DOI 10.3109/00365519609090583, PubMed 8837238

Eri LM, Wahlqvist R, Tveter KJ (1996)
[Diagnosis and treatment of benign prostatic hyperplasia in general practice. Norwegian Medical Society]
Tidsskr Nor Laegeforen, 116 (27), 3240-4
PubMed 9011979

Svindland A, Eri LM, Tveter KJ (1996)
Morphometry of benign prostatic hyperplasia during androgen suppressive therapy. Relationships among epithelial content, PSA density, and clinical outcome
Scand J Urol Nephrol Suppl, 179, 113-7
PubMed 8908676

Publications 1995

Berge V, Eri LM, Tveter KJ (1995)
Complications of invasive, urodynamic examinations and prostate biopsies in patients with benign prostatic hyperplasia
Scand J Urol Nephrol Suppl, 172, 95-8
PubMed 8578262

Eri LM, Haug E, Tveter KJ (1995)
Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia
Br J Urol, 75 (3), 335-40
DOI 10.1111/j.1464-410x.1995.tb07345.x, PubMed 7537602

Eri LM, Tveter KJ (1995)
alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia
J Urol, 154 (3), 923-34
DOI 10.1016/S0022-5347(01)66936-2, PubMed 7543612

Eri LM, Urdal P (1995)
Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia
Eur Urol, 27 (4), 274-9
DOI 10.1159/000475180, PubMed 7544732

Eri LM, Urdal P, Bechensteen AG (1995)
Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia
J Urol, 154 (1), 100-4
DOI 10.1016/S0022-5347(01)67239-2, PubMed 7539852

Publications 1994

Eri LM, Tveter KJ (1994)
Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia
J Urol, 152 (2 Pt 1), 448-52
DOI 10.1016/s0022-5347(17)32760-x, PubMed 7516978

Eri LM, Tveter KJ (1994)
Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia
Eur Urol, 26 (3), 219-26
DOI 10.1159/000475384, PubMed 7528662

Publications 1993

Eri LM, Tveter KJ (1993)
A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia
J Urol, 150 (1), 90-4
DOI 10.1016/s0022-5347(17)35406-x, PubMed 7685428

Eri LM, Tveter KJ (1993)
A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia
J Urol, 150 (2 Pt 1), 359-64
DOI 10.1016/s0022-5347(17)35483-6, PubMed 7686981

Publications 1992

Eri LM, Tveter KJ (1992)
Measuring the quality of life of patients with benign prostatic hyperplasia. Assessment of the usefulness of a new quality of life questionnaire specially adapted to benign prostatic hyperplasia patients
Eur Urol, 21 (4), 257-62
DOI 10.1159/000474853, PubMed 1281101

Eri LM, Tveter KJ (1992)
Patient recruitment to and cost of a prospective trial of medical treatment for benign prostatic hyperplasia
Eur Urol, 22 (1), 9-13
DOI 10.1159/000474714, PubMed 1385147

Publications 1988

Eri LM, Harbitz TB, Løtveit T (1988)
Pseudocyst of the spleen after closed abdominal injury
Injury, 19 (4), 297
DOI 10.1016/0020-1383(88)90057-5, PubMed 3229854

Eri LM, Klevmark B (1988)
[Urethral diverticulum in women]
Tidsskr Nor Laegeforen, 108 (12), 925-7
PubMed 3132747

Eri LM, Klevmark B (1988)
[Primary megaureter in adults]
Tidsskr Nor Laegeforen, 108 (12), 930-2
PubMed 3381207

Klevmark B, Talseth T, Eri LM, Borchgrevink HH, Kolbenstvedt A (1988)
[Congenital curvature of the erect penis without simultaneous changes in the urethra or corpus spongiosum and with normal erection]
Tidsskr Nor Laegeforen, 108 (8-9), 683-5
PubMed 3353973

Klevmark B, Talseth T, Eri LM, Kolbenstvedt A, Egge T (1988)
Abnormal venous drainage from the penis examined by dynamic cavernosography and surgically treated
Scand J Urol Nephrol Suppl, 110, 261-5
PubMed 3187421

Klevmark B, Talseth T, Eri LM, Kolbenstvedt AN (1988)
[Erectile impotence and disorders of venous circulation]
Tidsskr Nor Laegeforen, 108 (8-9), 679-80
PubMed 3353971

Publications 1987

Eri LM, Gjengedal E (1987)
[Surgical treatment of the impingement syndrome]
Tidsskr Nor Laegeforen, 107 (6), 543-4
PubMed 3576543

Eri LM, Liavåg I (1987)
[Subtotal cholecystectomy. An alternative to a difficult cholecystectomy]
Tidsskr Nor Laegeforen, 107 (5), 467-8
PubMed 3576533

Publications 1986

Eri LM, Sander S (1986)
[Primary hyperparathyroidism. Surgical case material from Aker Hospital 1974-85]
Tidsskr Nor Laegeforen, 106 (12), 1028-30
PubMed 3726830

Eri LM, Sander S, Rostad B, Bay D (1986)
[Preoperative localization of parathyroid tumors. CT and ultrasonics before surgery of primary hyperparathyroidism]
Tidsskr Nor Laegeforen, 106 (12), 1042-5
PubMed 3523823

Gjengedal E, Rolfsen L, Eri LM (1986)
[Acute total dislocation of the acromioclavicular joint. Surgical treatment]
Tidsskr Nor Laegeforen, 106 (30), 2515-7, 2530
PubMed 3798429

Publications 1985

Eri LM, Hoel R (1985)
[Adenocarcinoma of the colon and rectum. A population study]
Tidsskr Nor Laegeforen, 105 (9-10), 665-8
PubMed 3992555

Eri LM, Hvaal K, Gjølberg TO (1985)
[Percutaneous transluminal angioplasty in the lower limbs]
Tidsskr Nor Laegeforen, 105 (7), 503-6
PubMed 3158096

Publications 1984

Eri LM, Drabløs PA (1984)
[Inguinal hernia in children. Case material from a central hospital]
Tidsskr Nor Laegeforen, 104 (2), 81-3
PubMed 6701841